Sodium–glucose co-transporter 2 (SGLT2) inhibitors are licensed for the treatment of type 2 diabetes mellitus (T2DM); however, emerging evidence has also confirmed their powerful therapeutic effect against heart failure. Here, SLC5A2 is linked to type 2 diabetes mellitus.